71 related articles for article (PubMed ID: 15609199)
1. Testing assumptions of quality-adjusted life-year calculations. Commentary on "An Exponential Representation of Health State Utility" from M. Happich.
Béresniak A
Eur J Health Econ; 2003 Nov; 4(4):295. PubMed ID: 15609199
[No Abstract] [Full Text] [Related]
2. Composite measures for hospital quality using quality-adjusted life years.
Timbie JW; Shahian DM; Newhouse JP; Rosenthal MB; Normand SL
Stat Med; 2009 Apr; 28(8):1238-54. PubMed ID: 19184974
[TBL] [Abstract][Full Text] [Related]
3. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
4. Exponential health utility. A characterization and comments on the contribution by Happich and Muhlbacher.
Osterdal LP
Eur J Health Econ; 2004 Dec; 5(4):365-7. PubMed ID: 15549604
[TBL] [Abstract][Full Text] [Related]
5. Costs associated with ventricular assist device use in children.
Mahle WT; Ianucci G; Vincent RN; Kanter KR
Ann Thorac Surg; 2008 Nov; 86(5):1592-7. PubMed ID: 19049755
[TBL] [Abstract][Full Text] [Related]
6. Depression-free day to utility-weighted score: is it valid?
Pyne JM; Tripathi S; Williams DK; Fortney J
Med Care; 2007 Apr; 45(4):357-62. PubMed ID: 17496720
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and reliability of the annual profile method for deriving QALYs for short-term health conditions.
Janssen MF; Birnie E; Bonsel G
Med Decis Making; 2008; 28(4):500-10. PubMed ID: 18420835
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
[TBL] [Abstract][Full Text] [Related]
9. [How are quality-adjusted life years defined in German studies?].
Schwappach DL; Boluarte TA
Dtsch Med Wochenschr; 2006 Sep; 131(37):2004-9. PubMed ID: 16960766
[TBL] [Abstract][Full Text] [Related]
10. Do quality-adjusted life years take account of lost income? Evidence from an Australian survey.
Richardson J; Peacock SJ; Iezzi A
Eur J Health Econ; 2009 Feb; 10(1):103-9. PubMed ID: 18458973
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis applied to the treatment of burn patients in a specialized center.
Sánchez JL; Perepérez SB; Bastida JL; Martínez MM
Arch Surg; 2007 Jan; 142(1):50-7; discussion 57. PubMed ID: 17224500
[TBL] [Abstract][Full Text] [Related]
12. Management of influenza symptoms in healthy children: cost-effectiveness of rapid testing and antiviral therapy.
Rothberg MB; Fisher D; Kelly B; Rose DN
Arch Pediatr Adolesc Med; 2005 Nov; 159(11):1055-62. PubMed ID: 16275797
[TBL] [Abstract][Full Text] [Related]
13. An exponential representation of health state utility.
Happich M; Muehlbacher A
Eur J Health Econ; 2003 Nov; 4(4):292-4. PubMed ID: 15609198
[TBL] [Abstract][Full Text] [Related]
14. Predicting utility ratings for joint health States from single health States in prostate cancer: empirical testing of 3 alternative theories.
Dale W; Basu A; Elstein A; Meltzer D
Med Decis Making; 2008; 28(1):102-12. PubMed ID: 18057188
[TBL] [Abstract][Full Text] [Related]
15. Healthy-years equivalent: wounded but not yet dead.
Hauber AB
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):265-9. PubMed ID: 19527099
[TBL] [Abstract][Full Text] [Related]
16. Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
[TBL] [Abstract][Full Text] [Related]
17. Advantages and limitations of utility assessment methods in rheumatoid arthritis.
Beresniak A; Russell AS; Haraoui B; Bessette L; Bombardier C; Duru G
J Rheumatol; 2007 Nov; 34(11):2193-200. PubMed ID: 17937471
[TBL] [Abstract][Full Text] [Related]
18. A note on the nature of utility in time and health and implications for cost utility analysis.
Buckingham KJ; Devlin NJ
Soc Sci Med; 2009 Jan; 68(2):362-7. PubMed ID: 19019518
[TBL] [Abstract][Full Text] [Related]
19. Costs and quality of life for patients with multiple sclerosis in Belgium.
Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
[TBL] [Abstract][Full Text] [Related]
20. Treatment for patients with rectal cancer and a clinical complete response to neoadjuvant therapy: a decision analysis.
Neuman HB; Elkin EB; Guillem JG; Paty PB; Weiser MR; Wong WD; Temple LK
Dis Colon Rectum; 2009 May; 52(5):863-71. PubMed ID: 19502849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
